Mar 2018

NATIONAL EVIDENCE REVIEW RELEASED

The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development of new clinical guidance documents for medicinal cannabis products. It includes a national review of the scientific evidence for the use of cannabis medicines in five areas: palliative care, nausea and vomiting, epilepsy, multiple sclerosis and pain.

More information is available on the TGA website and can be found here.

One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.

READ MORE >

In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.

READ MORE >

What’s most important in business – purpose or profit? At ANTG we get to achieve both.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >